Predictors and Outcomes of Vitrectomy and Silicone Oil Injection in Advanced Diabetic Retinopathy

PURPOSE: To evaluate visual and anatomical results and identify factors that influence vitrectomy and silicone oil (SO) injection outcomes in proliferative diabetic retinopathy (PDR). METHODS: This retrospective study included 236 eyes with PDR that were undergoing vitrectomy and SO injection with >3-month follow-up. The primary outcomes were final best-corrected visual acuity (BCVA) and retinal attachment rate. RESULTS: At the final visit (mean, 88 ± 58 weeks), complete, partial, and no retinal attachment were observed in 86.9%, 10.6%, and 2.5% of patients, respectively. A total of 155 eyes had experienced SO removal, while 81 had SO in place. The mean initial BCVA was 1.9 ± 0.7 logarithm of the minimum angle of resolution (logMAR) and significantly improved to 1.7 ± 0.8 logMAR (p = 0.001). Initial macular detachment (adjusted odds ratio [AOR], 0.25), development of iatrogenic break (AOR, 0.25), and use of heavy SO (AOR, 0.13) were independently associated with a lower risk of final retinal attachment, and SO removal was associated with a higher incidence (AOR, 7.55). Better baseline BCVA was associated with a higher risk of final BCVA ≥20 / 200. CONCLUSIONS: Despite an encouraging outcome based on anatomical data in advanced PDR treated with vitrectomy and SO, the functional prognosis was not satisfying for patients. Eyes with better vision at baseline had a more favorable prognosis, whereas eyes with initial macular detachment, intraoperative iatrogenic break, or heavy SO showed more unfavorable outcomes. In selected cases, extending the time of SO use did not worsen the prognosis.

Analgesic Effect of Topical Sodium Diclofenac before Retinal Photocoagulation for Diabetic Retinopathy: A Randomized Double-masked Placebo-controlled Intraindividual Crossover Clinical Trial

PURPOSE: To evaluate the analgesic effect of topical sodium diclofenac 0.1% before retinal laser photocoagulation for diabetic retinopathy. METHODS: Diabetic patients who were candidates for peripheral laser photocoagulation were included in a randomized, placebo-controlled, intraindividual, two-period, and crossover clinical trial. At the first session and based on randomization, one eye received topical sodium diclofenac 0.1% and the other eye received an artificial tear drop (as placebo) three times before laser treatment. At the second session, eyes were given the alternate drug. Patients scored their pain using visual analogue scale (max, 10 cm) at both sessions. Patients and the surgeon were blinded to the drops given. Difference of pain level was the main outcome measure. RESULTS: A total of 200 eyes of 100 patients were enrolled. Both treatments were matched regarding the applied laser. Pain sensation based on visual analogue scale was 5.6 ± 3.0 in the treated group and 5.5 ± 3.0 in the control group. The calculated treatment effect was 0.15 (95% confidence interval, −0.27 to 0.58; p = 0.486). The estimated period effect was 0.24 (p = 0.530) and the carryover effect was not significant (p = 0.283). CONCLUSIONS: Pretreatment with topical sodium diclofenac 0.1% does not have any analgesic effect during peripheral retinal laser photocoagulation in diabetic patients.

Intravitreal Bevacizumab for Treatment of Refractory Central Serous Choroidoretinopathy

In a clinical case series, 5 patients with not-resolved central serous choroidoretinopathy (CSC) lasting more than 1 year received one intravitreal bevacizumab injection (IVB, 1.25 mg) injection. All patients underwent a through ophthalmic examination 1 day, 1 week, and 1, 2, and 6 months after the injection. Best corrected visual acuity (BCVA) and central macular thickness were compared before and after treatment by optical coherence tomography. Mean BCVA was improved significantly (p = 0.020) from 0.60 +/- 0.25 to 0.50 +/- 0.18 and 0.29 +/- 0.19 logarithm of minimum angle of resolution at 6 and 18 weeks, respectively. Central macular thickness was also decreased significantly (p = 0.010) from 370 +/- 65 to 208 +/- 23 microm at 4 months. No recurrence was occurred during follow-up. IVB injection may have beneficial effect in the treatment of refractory CSC.

Intravitreal triamcinolone for acute branch retinal vein occlusion: a randomized clinical trial

To evaluate the therapeutic effect of intravitreal triamcinolone [IVT] injection for recent branch retinal vein occlusion [BRVO]. In a randomized controlled clinical trial, 30 phakic eyes with recent [less than 10 weeks' duration] BRVO were assigned to two groups. The treatment group [16 eyes] received 4 mg IVT and the control group [14 eyes] received subconjunctival sham injections. Changes in visual acuity [VA] were the main outcome measure. VA and central macular thickness [CMT] changes were not significantly different between the study groups at any time point. Within group analysis showed significant VA improvement from baseline in the IVT group up to three months [P < 0.05]; the amount of this change was 0.53 +/- 0.46, 0.37 +/- 0.50, 0.46 +/- 0.50, and 0.29 +/- 0.45 logMAR at 1, 2, 3, and 4 months, respectively. Corresponding VA improvements in the control group were 0.20 +/- 0.37, 0.11 +/- 0.46, 0.25 +/- 0.58, and 0.05 +/- 0.50 logMAR [all P values > 0.05]. Significant reduction in CMT was noticed only in the treatment group [-172 +/- 202 micro m, P = 0.029] and at 4 months. Ocular hypertension occurred in 4 [25%] and 2 [14.3%] eyes in the IVT and control groups, respectively. A single IVT injection had a non-significant beneficial effect on VA and CMT in acute BRVO as compared to the natural history of the condition. The 3-month deferred treatment protocol advocated by the Branch Vein Occlusion Study Group may be a safer option than IVT injection considering its potential side effects

Characteristics and surgical outcomes of rhegmatogenous retinal detachment following myopic LASIK

To describe the clinical features and surgical outcomes of rhegmatogenous retinal detachment [RRD] following myopic laser in situ keratomileusis [LASIK]. In a retrospective, non-comparative case series, 46 eyes that had undergone vitreoretinal surgery for management of RRD following myopic LASIK were identified. Data was reviewed with emphasis on characteristics of the RRD, employed surgical techniques, and anatomic and visual outcomes. Mean pre-LASIK myopia was -9.7 +/- 3.9 [range -4.00 to -18.00] diopters [D]. Mean interval between LASIK and development of RRD was 11.6 +/- 11.2 months. Posterior vitreous detachment was present in 44 eyes [95.6%]. The retinal breaks included flap tears in 36 [78.3%] eyes, giant tears in 8 [17.4%] eyes and atrophic holes in 2 [4.3%] eyes. In eyes with flap tears, the breaks were multiple, large or posterior to the equator in 24 [66.7%] eyes. Retinal breaks were related to lattice degeneration in 20 [43.5%] eyes of which, three had history of prophylactic barrier laser photocoagulation. Scleral buckling was performed as the initial procedure in 32 [69.6%] eyes and primary vitrectomy was undertaken in 14 [30.4%] eyes. The initial surgical procedure failed in 14 [30.4%] eyes due to proliferative vitreoretinopathy [PVR]. Retinal reattachment was finally achieved in 43 [93.4%] eyes. Postoperative visual acuity >/= 20/40 and >/= 20/200 was achieved in 16 [34.8%] and 25 [54.3%] eyes, respectively. Post-LASIK retinal detachment has a complex nature in eyes with moderate to high myopia. The retinal detachment is complex in terms of size, number and location of retinal breaks, is associated with a high rate of PVR and entails unfavorable visual outcomes